Factory 99% Tenofovir Disoproxil Fumarate Powder CAS 202138-50-9 Chemical Intermediate

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A822
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Tenofovir Disoproxil Fumarate
• CAS: 202138-50-9
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Tenofovir Disoproxil Fumarate
Appearance	White Powder
CAS NO.	202138-50-9
Storage	Keep in a cool, dry, dark location

 

Tenofovir Disoproxil Fumarate is an antiviral medication used primarily in the treatment of HIV-1 infection and chronic hepatitis B. It is a nucleotide reverse transcriptase inhibitor (NRTI) that acts by inhibiting the activity of HIV-1 reverse transcriptase and HBV polymerase, thereby blocking viral replication.

 

1. HIV-1 Infection: Tenofovir Disoproxil Fumarate is indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients aged 2 years and older.
2. Chronic Hepatitis B: It is also approved for the treatment of chronic hepatitis B in adults with compensated liver disease.
3. Combination Therapy: It is often used as part of a combination antiretroviral therapy (cART) regimen to maximize viral suppression and reduce the risk of drug resistance.

1. Inhibition of Reverse Transcriptase: Tenofovir Disoproxil Fumarate is metabolized intracellularly to tenofovir diphosphate, which competitively inhibits HIV-1 reverse transcriptase and HBV polymerase.
2. Viral Replication Blockade: By inhibiting these enzymes, Tenofovir Disoproxil Fumarate disrupts the viral replication cycle, preventing the virus from multiplying and spreading within the body.
3. Improved Clinical Outcomes: The use of Tenofovir Disoproxil Fumarate has been associated with improved virologic response, increased CD4+ T-cell counts, and reduced morbidity and mortality in patients with HIV-1 infection. Additionally, it has demonstrated antiviral activity and histologic improvement in patients with chronic hepatitis B.